Genesis Therapeutics
Genesis Therapeutics is a biotechnology company that uses its proprietary GEMS AI platform to discover small molecule drugs for severe diseases.
Secondary Market Price
Secondary Market Price
How Genesis Therapeutics Measures Up
To help you manage your Genesis Therapeutics equity, Prospect has run the company through our machine learning model.
Prospect Rating
TBD
We are still in the process of evaluating Genesis Therapeutics and are gathering more data. Check back soon for our official rating on what we believe the company will be worth in four years.
Exit Risk
TBD
We are still gathering data on Genesis Therapeutics to train our machine learning model. Check back soon for our exit risk rating for Genesis Therapeutics!
Funding Stage
Series B
Since Genesis is in its Series B stage, it has moved beyond the initial startup risks, offering more stability than a company just starting out. This means you'll be joining an established team that is still in a high-growth phase, creating significant opportunities for you to make an impact and advance your career.
Secondary Market Price Chart
The secondary market prices for Genesis Therapeutics shown here are a limited preview. Create a free account to access real-time secondary market prices
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Genesis Therapeutics Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Genesis Therapeutics's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Genesis Therapeutics is a biotechnology research company that uses artificial intelligence to accelerate the discovery of small-molecule drugs. The company’s core technology is its proprietary GEMS (Genesis Exploration of Molecular Space) platform, which combines deep learning models, molecular simulations, and generative AI to identify and optimize drug candidates. This platform is applied to build an internal pipeline of programs, including those aimed at historically difficult or "undruggable" targets. Founded in 2019 by Evan Feinberg and Ben Sklaroff, the company is headquartered in Burlingame, California, and operates a fully integrated laboratory in San Diego.
The company has established several significant collaborations with major pharmaceutical firms, including a 2020 agreement with Genentech, a 2022 partnership with Eli Lilly, and a 2024 deal with Incyte valued at up to $885 million. These partnerships leverage the GEMS platform to advance drug discovery across various therapeutic areas. Genesis Therapeutics has also secured substantial financial backing, raising over $280 million in total funding. This includes a $200 million Series B round in 2023 with participation from investors such as Andreessen Horowitz, T. Rowe Price, and NVentures, NVIDIA's venture capital arm.
- Andreessen Horowitz
- Felicis
- Rock Springs Capital
- Co-Founder, CEO Evan Feinberg
- Co-Founder, Brendan Frey
- Co-Founder, Vikram Mulligan
- Co-Founder, David Minikel
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Genesis Therapeutics worth joining?
Determining if a private company is worth joining depends on its growth potential, financial health, and your personal career goals. Platforms like Prospect offer data-driven insights and projections on private companies to help you make a more informed decision.
What should I do with my Genesis Therapeutics stock?
Deciding what to do with private company stock requires evaluating your financial goals, the company's performance, and the associated tax implications. Prospect provides tools to help you model different scenarios and create tax-optimized strategies for exercising options or selling shares.
Can you sell Genesis Therapeutics stock?
As Genesis Therapeutics is a private company, its stock is not on public exchanges, but employees can sometimes sell shares through secondary markets or company-approved tender offers. Platforms like Prospect offer tools and access to secondary market pricing to help you navigate these selling opportunities.
How can I find the value of my Genesis Therapeutics stock?
The value of private stock is typically based on the company's most recent 409A valuation or the price from its latest funding round. To get a forward-looking estimate, Prospect uses predictive models trained on venture capital data to project the future value of your shares.
What is Genesis Therapeutics's equity worth?
The worth of Genesis Therapeutics's equity is tied to its private valuation, which changes with new funding rounds, company performance, and overall market conditions. You can use Prospect's equity calculator and proprietary models to get a personalized projection of what your equity holdings could be worth.
What is Genesis Therapeutics's stock ticker symbol?
Because Genesis Therapeutics is a private company, it does not have a stock ticker symbol. Ticker symbols are assigned only when a company lists its shares for trading on a public stock exchange.
Can I buy or sell Genesis Therapeutics stock?
Buying or selling stock in a private company like Genesis Therapeutics is restricted and usually occurs through secondary markets or tender offers, which are less common than public market trading. Prospect offers tools to help existing equity holders decide how much to sell and identify the most tax-optimal shares for a transaction.
What is the criteria to buy or invest in Genesis Therapeutics stock?
Investing in a private company is typically limited to accredited investors participating in funding rounds or employees who receive equity as compensation. While Prospect does not facilitate investments, it provides analytical tools to help you evaluate the potential of such opportunities.
